Health TrialsbyHealthPanel

KMT2A-rearranged

2

Review clinical trials related to KMT2A-rearranged. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

Participants needed: 24
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Oct 8, 2026Locations: 2
Eligibility criteria

Age ≥16 years during dose escalation portion of study, patients must weigh ≥40 k... [+13]

AML diagnosis without KMT2A-rearrangement or NPM1-mutation. KMT2A-PTD patients a... [+18]

Read more
Status: Not yet recruiting

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.

Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Aug 12, 2026Locations: 1
Eligibility criteria

Participants > 18 years of age with relapsed and/or refractory (defined as >5% b... [+25]

Active serious infection not controlled by oral or IV antibiotics [+9]

Read more